Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party  by Robin, Marie et al.
Biol Blood Marrow Transplant 21 (2015) 489e495Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgComparison of Unrelated Cord Blood and Peripheral Blood
Stem Cell Transplantation in Adults with Myelodysplastic
Syndrome after Reduced-Intensity Conditioning Regimen: A
Collaborative Study from Eurocord (Cord blood Committee of
Cellular Therapy & Immunobiology Working Party of EBMT)
and Chronic Malignancies Working PartyMarie Robin 1,*, Annalisa Ruggeri 2,3, Myriam Labopin 4, Dietger Niederwieser 5, Reza Tabrizi 6,
Guillermo Sanz 7, Jean-Henri Bourhis 8, Anja van Biezen 9, Christian Koenecke 10, Didier Blaise 11,
Johanna Tischer 12, Charles Craddock 13, Natacha Maillard 14, Mohamad Mohty 3,15, Nigel Russel 16,
Johannes Schetelig 17, Jürgen Finke 18, Eliane Gluckman2, Theo M. de Witte 19, Vanderson Rocha 2,
Nicolaus Kroger 20
1Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France
2 Eurocord International Registry, Hôpital Saint-Louis, Paris, France
3 Service d’hématologie et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
4 EBMT Ofﬁce, Hospital Saint Antoine, Universite Pierre et Marie Curie, Paris, France
5Division of Hematology and Medical Oncology, University of Leipzig, Leipzig, Germany
6Hôpital Haut-Lévêque, Hématologie clinique et thérapie celllulaire, Pessac Cedex, France
7Hematology Department, Hospital Universitario La Fe, Valencia, Spain
8Hematology, Institut Gustave Roussy, Villejuif, France
9 EBMT Clinical Trials & Study Ofﬁce, Leiden, Netherlands
10Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
11Hematology, Institut Paoli Calmettes, Marseille, France
12 Ludwig-Maximilians University of Munich, Klinikum Großhadern, Medizinische Klinik III, München, Germany
13Center for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, United Kingdom
14CHU Hematology, Poitiers, France
15 EBMT Acute Leukemia Working Party and Registry, Hospital Saint-Antoine, Paris University, Paris, France
16Nottingham University Hospital, Nottingham, United Kingdom
17Medical Clinic I, University Hospital, Dresden, Germany
18Department of Hematology/Oncology, University Hospital Freiburg, Freiburg, Germany
19Department of Tumor Immunology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands
20Center of Oncology-Bone Marrow Transplantation Unit, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyArticle history:
Received 15 September 2014
Accepted 22 November 2014
Key Words:
Myelodysplastic syndrome
Cord blood transplant
Reduced-intensity conditioning
regimen
Alternative donorsFinancial disclosure: See Acknowle
* Correspondence and reprint
Transplantation, Saint-Louis Hosp
Paris, France.
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment in patients with higher
risk myelodysplastic syndrome (MDS), but the choice of the optimal alternative stem cell source is still a
subject of debate in patients lacking an HLA-matched sibling donor. Here, we report on a large series of
patients with MDS (N ¼ 631) transplanted either with mobilized peripheral stem cells (PBs) from unrelated
donors (n ¼ 502) or with umbilical cord blood transplant (UCB, n ¼ 129) as alternative grafts after reduced-
intensity conditioning. Neutrophil engraftment was higher after PB (98% versus 78%, P < .0001). Acute graft-
versus-host disease (GVHD) was similar after PB (31%) and UCB (29%), and chronic GVHD incidence was
higher after PB (41% versus 23%). Two-year nonrelapse mortality was lower after PB (31% versus 42% P ¼ .03).
There was a better overall survival (OS) and disease-free survival (DFS) after PB (49%  2% versus 30%  4%,
P < .0001 and 44%  2% versus 28%  4%, P < .0001). Multivariate analysis conﬁrmed the advantage of PB for
treatment-related mortality, OS, and DFS, whereas relative risk of chronic GVHD was similar. A multivariate
analysis comparing PB from a 10/10 HLA-matched donor, PB from a 9/10 HLA-matched donor, and UCBdgments on page 494.
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M. Robin et al. / Biol Blood Marrow Transplant 21 (2015) 489e495490showed an advantage on treatment-related mortality, DFS, and OS only in 10/10 PB. We conclude that in MDS
patients lacking an HLA-matched sibling donor, PB from a 10/10 HLA-matched unrelated donor is the
preferred source of hematopoietic stem cells. HLA-mismatched unrelated donor or cord blood seem to give
similar inferior results except for neutrophil engraftment, which is delayed after UCB.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Myelodysplastic syndrome (MDS) is a hematological
malignancy resulting in ineffective hematopoietic trans-
plantation and leading to acute leukemia in a substantial
proportion of patients. Patients with MDS have an expected
survival that ranges from a fewmonths tomore than 10 years
depending on prognostic factors. In particular cytogenetics,
cytopenia and blast count are used to calculate the Interna-
tional Prognostic Scoring System (IPSS) [1]. According to the
IPSS, for patients with higher risk MDS (intermediate-2 or
high), life expectancy is lower than 3 years, and allogeneic
hematopoietic stem cell transplantation (HSCT) is the only
curative option [2]. Because these patients are in median
older than 60 years, a reduced-intensity conditioning
regimen (RIC) has been increasingly used, resulting in long-
term survival in approximately one third of them, with re-
lapses remaining the primary cause of treatment failure
followed by toxicity and infection [3-5].
For patients who need an HSCT and lack a suitable HLA-
matched sibling donor, alternative donor graft sources such
as an unrelated donor or unrelated umbilical cord blood
(UCB) can be considered [6]. Transplantation from an unre-
lated donor is limited by HLA matching and donor avail-
ability, whereas UCB is more easily available with less HLA
barrier, increasing probability to identify 1 or 2 suitable cord
blood units.
Furthermore, graft-versus-host disease (GVHD) incidence
has been reported to be lower after UCB than after use of an
unrelated donor. This can be particularly important for long-
term quality of life. We reported encouraging results in 108
MDS patients transplanted with UCB with a decreased non-
relapse mortality (NRM) in patients receiving RIC and a 2-
year overall survival (OS) rate of 35% [7]. Currently, there is
no report comparing results of transplantation using unre-
lated donor and cord blood in MDS patients. We report here
the outcome of a large cohort of MDS patients who received
HSCT after a RIC using as graft source either granulocyte
colony-stimulating factor peripheral blood (PB) from an
unrelated donor or UCB.
METHODS
Data Collection
Data were obtained from the European Group for Blood and Marrow
Transplantation (EBMT) or Eurocord registries. The MDS subcommittee of
the Chronic Malignancies Working Party and Eurocord both approved this
study, which was performed according to the Declaration of Helsinki.
All patients gave written consent for their data registration. Data were
extracted by the EBMT ofﬁce from PROMISE and Eurocord, and a question-
naire was sent to transplant centers to conﬁrm HLA typing and request for
the last follow-up status.
Patient Selection
This study included adult patients (age  18 years) with a diagnosis of
MDS (de novo or secondary) according to the World Health Organization
deﬁnitionwho received a RIC according to the EBMT deﬁnition from January
2005 to December 2011. Patients received an allograft from either unrelated
donor PB or unrelated unmanipulated single- or double-unit UCB. Only
patients with sufﬁcient information of HLA typing were included: 10 anti-
gens HLA-A, -B, -C, -DRB1, and -DQB1 at the allele level for PB stem cell or
HLA-A and -B at the antigen level and -DRB1 at the allele level for UCB.Patients who received haploidentical grafts were excluded. Cytogenetics at
time of transplant were also available.
Deﬁnitions of Outcome
Neutrophil recovery was deﬁned as achieving an absolute neutrophil
count >.5  109/L on 3 consecutive days. Grades of acute and chronic GVHD
were assigned using standard criteria [8,9], because data to determine Na-
tional Institutes of Health chronic GVHD classiﬁcations were not available
for most patients. NRM was deﬁned as death occurring in the absence of
MDS relapse. MDS relapse was deﬁned by cytological morphological
evidence.
Statistical Analysis
Primary endpoints were disease-free survival (DFS), relapse incidence
(RI), NRM, and OS. Secondary endpoints were engraftment and acute and
chronic GVHD. DFS was deﬁned as survival with no evidence of relapse or
progression. NRM was deﬁned as death without evidence of relapse or
progression. OS was deﬁned as the time from HSCT to death, regardless of
the cause.
Patient-, disease-, and transplant-related variables were compared be-
tween the 2 groups receiving PB or UCB using the chi-square statistic for
categorical variables and the Mann-Whitney test for continuous variables.
Variables considered were source of stem cells; cytogenetics categorized as
good (reference), intermediate, poor, or acute myelogenous leukemia (AML;
patients with MDS transformed into AML were not classiﬁed by IPSS);
patient gender and age; time from diagnosis to transplantation; type of
conditioning regimen (total body irradiation [TBI] versus non TBI); and
previous autologous transplantation.
Probabilities of DFS and OS were calculated using the Kaplan-Meier
estimates. Cumulative incidence functions were used to estimate RI and
NRM in a competing risks setting, because death and relapse compete with
each other. To study engraftment and chronic GVHD, we considered death to
be a competing event. Univariate analyses were performed using Gray’s test
for cumulative incidence functions and the log-rank test for DFS and OS.
Associations of patient and graft characteristics with outcomes were eval-
uated in multivariate analysis, using logistic regression for acute GVHD and
Cox proportional hazards model for other endpoints.
All factors that differed signiﬁcantly between the 2 groups with P < .05
were included in the ﬁnal models. All tests were 2-sided. The Type I error
rate was ﬁxed at .05 for determination of factors associated with time to
event outcomes. Statistical analyses were performed with SPSS 19 (SPSS
Inc./IBM, Armonk, NY) and R 3.0.1 (R Development Core Team, Vienna,
Austria).
RESULTS
Patients
Among the 631 recipients, 502 received PB and 129 UCB
as the source of stem cells. Among the 129 patients who
received UCB, 80 received 2 units and 49 a single unit ac-
cording to each center policy. Baseline patient characteris-
tics according to the source of stem cells are shown in
Table 1. Patients transplanted with PB were older (60 versus
57 years, P < .0001) and were less often transformed into
AML at the time of transplantation (64% versus 71%, P ¼ .04).
MDS World Health Organization classiﬁcation was
refractory anemia in 37, refractory cytopenia with multi-
lineage dysplasia in 31, refractory anemia with excess blasts-
1 in 50 and refractory anemia with excess blasts-2 in 87, and
unclassiﬁed in 10 patients. Considering only patients who
were not transformed into AML, the cytogenetic score ac-
cording to IPSS was good in 96, intermediate in 57, and poor
in 65 patients. Approximately half of the patients with MDS
who transformed into AML were in complete remission at
Table 1
Patients and Transplantation Characteristics
Characteristics PB Group UCB Group P
Total number of patients 502 129
Median age, yr (range) 60 (20-76) 57 (20-72) <.0001
Number of men 308 (61) 59 (47) .003
Female donor-to-male recipient <.0001
Yes 74 (15) 39 (34)
Missing 6 (1) 13 (10)
Transformation into AML before the transplantation 321 (64) 92 (71) .04
Cytogenetic according to IPSS in patients with MDS at time of transplantation .04
Good 86 (48) 10 (27)
Intermediate 42 (23) 15 (41)
Poor 53 (29) 12 (32)
Time from diagnosis to transplantation, days (range) 310 (40-6300) 322 (71-6838) .08
Year of transplantation 2010 2009 .08
CMV positive serology 310 (62) 80 (69) .16
T cell depletion in vivo 417 (83) 47 (40) <.0001
Antithymocyte globulin in conditioning regimen 304 46
Alemtuzumab 113 1
Missing 1 11 (8)
Low-dose TBI in conditioning regimen 110 (22) 90 (70) <.0001
Conditioning regimen <.0001
Fludarabine and melphalan 125 (25) 7 (6)
Fludarabine and busulfan 213 (42) 1 (1)
Fludarabine and TBI 62 (12) 1 (1)
Fludarabine and TBI 2 Gy and cyclophosphamide 39 (8) 79 (65)
Other 63 (13) 41 (28)
GVHD prophylaxis <.0001
Cyclosporine and mycophenolate mofetil  other 237 (48) 97 (75)
Cyclosporine and methotrexate  other 98 (18) 5 (4)
Cyclosporine alone or with steroids 124 (25) 11 (9)
Other 43 (9) 16 (12)
Previous autologous transplantation 22 (4) 12 (9) .03
CMV indicates cytomegalovirus.
Values are number of cases with percents in parentheses, unless otherwise indicated.
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for UCB).
Among the PB recipients, HLA matching with the recip-
ient was 10/10 in 379 (75%), 9/10 in 107 (21%), and less thanTable 2
Characteristics of Patients Receiving Either PB 10/10 HLA-Matched Donor or 9/10 H
Characteristics
Total number of patients
Median age, yr (range)
Number of men
Female donor-to-male recipient
Transformation into AML before the transplantation
Cytogenetic according to IPSS in patients with MDS at time of transplantation
Good
Intermediate
Poor
Time from diagnosis to transplantation, days (range)
Year of transplantation
CMV positive serology
T cell depletion in vivo
Antithymocyte globulin in conditioning regimen
Alemtuzumab
Low-dose TBI in conditioning regimen
Conditioning regimen
Fludarabine and melphalan
Fludarabine and busulfan
Fludarabine and TBI
Fludarabine and TBI 2 Gy and cyclophosphamide
Other
GVHD prophylaxis
Cyclosporine and mycophenolate mofetil  other
Cyclosporine and methotrexate  other
Cyclosporine alone or with steroids
Other
Previous autologous transplantation
Values are number of cases with percents in parentheses, unless otherwise indica9/10 in 16 (3%) patients. Baseline characteristics of patients
receiving PB according to the HLA matching are shown in
Table 2. Most UCB (n¼ 126, 98%) recipients had at least 1 HLA
mismatch on 6 antigens (HLA-A and -B antigen level andLA-Matched Donor
PB 10/10 HLA-Matched Donor PB 9/10 HLA-Matched Donor P
379 107
60 (24-76) 61 (20-74) .77
232 (61) 69 (65) .47
57 (15) 14 (14) .67
242 (64) 68 (64) .95
.29
61 (44) 22 (56)
31 (23) 9 (23)
45 (33) 8 (21)
312 (40-6300) 302 (48-4249) .66
2010 2009 .24
234 (62) 66 (62) .98
309 (82) 93 (87) .21
230 64
79 29
85 (22) 21 (20) .54
.67
89 (23) 30 (28)
161 (42) 48 (45)
48 (13) 11 (10)
30 (8) 8 (8)
51 (14) 10 (9)
.31
171 (45) 56 (52)
82 (22) 15 (14)
93 (24) 28 (26)
33 (9) 8 (8)
18 (5) 3 (3) .38
ted.
Table 3
Outcome Estimation According to the Type of Donor: Unrelated Donor HLA 10/10, Unrelated Donor HLA 9/10, or UCB
Groups Neutrophil Recovery
Incidence (95% CI)
Chronic GVHD
Incidence (95% CI)
OS (95% CI) DFS (95% CI) RI (95% CI) Non-RI (95% CI)
HLA 10/10 97 (96-98) 44 (41-47) 50 (47-53) 45 (42-48) 23 (21-25) 32 (30-34)
HLA 9/10 97 (95-99) 37 (31-43) 43 (38-48) 36 (30-42) 28 (23-33) 36 (31-41)
UCB 78 (74-82) 23 (19-27) 30 (26-34) 28 (24-32) 30 (24-34) 42 (38-46)
Overall P <.0001 .004 <.0001 <.0001 .47 .04
P value for
HLA 10/10 vs. CB <.0001 .002 <.0001 <.0001 .1 .02
HLA 9/10 vs. CB <.0001 .03 .05 .03 .32 .33
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85 (66%) had 2 HLA mismatches. Median nucleated cell
number at collectionwas 9.6 108/kg (range,1.5 to 33.20) for
PB and 4.58  107/kg (range, 1.4 to 13) for UCB.
Conditioning regimen characteristics are summarized in
Table 1. The most commonly used regimens were the com-
bination of ﬂudarabine and busulfan in PB recipients (42%)
and 2-Gy TBI, cyclophosphamide and ﬂudarabine for UCB
recipients (65%). Antithymocyte globulin was more
frequently used in the PB group (83 versus 40%, P < .0001),
whereas TBI was less frequently used (22 versus 70%,
P < .0001). Cyclosporine-based GVHD prophylaxis was the
more often used associated with mycophenolate mofetil in
237 of 502 recipients (48%) of PB transplants and 97 of 129
(75%) recipients of UCB transplants (Table 1). The period of
transplantation was not signiﬁcantly different between PB
and UCB transplants (median year of transplantation: 2010
for PB and 2009 for CB).Engraftment and GVHD
The cumulative incidence of neutrophil recovery was
signiﬁcantly improved with PB (98%; 95% conﬁdence interval
[CI], 97 to 99) thanwith UCB (78%; 95% CI, 74 to 82, P< .0001)
(Table 3). The cumulative incidence of engraftment did not
differ for patients receiving single or double UCB (77% versus
79%, P ¼ .18) and for patients receiving total nucleated cells
>4.58 107/kg (median) (76% versus 78%, P¼ .87). The delay
for neutrophil recovery was shorter after PB (16 days [range,
3 to 60] versus 20 days [range, 6 to 72], P < .0001).
The cumulative incidence of day 100 grades II to IV acute
GVHD incidence was similar in both groups (PB, 29%; UCB,
31%). In a multivariate analysis, after adjustment for differ-
ences, stem cell source remained not signiﬁcantly associated
with the risk of acute GVHD. The cumulative incidence of 2-
year chronic GVHD was signiﬁcantly lower after UCB trans-
plants (23%  4%) compared with PB transplants (41%  2%)
(Table 3). Chronic GVHD was extensive in 11 of 25 UCB re-
cipients (44%) and in 56 of 131 PB recipients (43%). After
adjustment, patients transplanted with PB or UCB have a
similar risk to develop chronic GVHD. When comparing
chronic GVHD in patients receiving 10/10 PB, 9/10 PB, and
UCB, patients were at the highest risk for development of
chronic GVHD after 9/10 PB (44%  3%, 37%  6%, versus
23%  4%, respectively). Chronic GVHD had no impact on RI
(hazard ratio [HR], .88; 95% CI, .55 to 1.41; P ¼ .59) in a time-
dependent fashion.Figure 1. NRM according to the source of stem cells: PB HLA 10/10, PB HLA 9/
10, and UCB (CBT).Mortality
After a median follow-up of 25 and 24 months for the
recipients of PB and UCB transplants, respectively, 346 of
631 patients died: 52% in the PB group and 68% in the CB
group. The most frequent cause of death was relapse (33% inPB and 37.5% in UCB) followed by infections (17% for PB
versus 21% in UCB). GVHD was a more frequent cause of
death in the PB group (18% versus 10%, not signiﬁcant [ns]),
whereas organ failure was less common in the PB group (6%
versus 19%, ns). Second malignancy was a cause of death in
2% of patients from the PB group and 2% of patients from
the UCB group. Causes of death were missing in 46 patients
(18%) from the PB group and in 4 patients (4.5%) from the
UCB group.
Two-year NRMwas lower in the PB group than in the UCB
group (31%  2% versus 42%  5%, P ¼ .03) (Table 3). After
adjusting for other variables, NRM risk remained signiﬁ-
cantly lower in the PB than in the UCB group (HR, 1.68; 95%
CI, 1.16 to 2.43; P ¼ .006), and no other factor signiﬁcantly
impacted the NRM risk (Table 3). For the group of patients
transplanted with PB from either an HLA 9/10 or 10/10
matched unrelated donor, NRM was 36%  5% and 32%  2%,
respectively, and was signiﬁcant lower using 10/10 matched
grafts as compared with UCB (10/10 versus UCB, P¼ .02; 9/10
versus UCB, P ¼ .33; Figure 1). In multivariate analysis
comparing UCB, 9/10 PB, and 10/10 PB, the NRM risk was
higher when comparing 10/10 PB to UCB (HR, .57; 95% CI, .39
to 0.83; P ¼ .003) and similar between 9/10 PB and UCB (HR,
.71; 95% CI, .44 to 1.15; P ¼ .16).Relapse and Progression
Overall, 162 patients relapsed or progressed after the
transplantation, 122 in the PB and 40 in UCB group. Of note,
only 273 of 631 patients (43%) in the whole series were
Table 4
Multivariate Analysis for Outcome Comparing Source of Hematopoietic
Stem Cell
Characteristics P HR 95% CI
OS UCB (reference) 1.00
UD 10/10 vs. UCB .0001 .56 .41 .75
UD 9/10 vs. UCB .10 .73 .50 1.06
Cytogenetics
Good (reference) 1.00
Intermediate .52 1.17 .72 1.90
Poor .01 1.75 1.12 2.74
sAML .07 1.37 .98 1.93
Patient gender (female vs. male) .02 .76 .60 .95
Age > median .21 1.15 .92 1.45
Time from diagnosis to transplant
> median
.22 .87 .70 1.09
TBI in conditioning regimen .34 1.14 .87 1.48
Previous autograft .55 1.15 .73 1.80
DFS UCB (reference) 1.00
UD 10/10 vs. UCB .0002 .57 .43 .76
UD 9/10 vs. UCB .06 .70 .49 1.01
Cytogenetics
Good (reference) 1.00
Intermediate .91 1.03 .65 1.63
Poor .01 1.73 1.13 2.64
sAML .17 1.25 .91 1.72
Patient gender (female vs. male) .04 .79 .63 .98
Age > median .29 1.12 .91 1.40
Time from diagnosis to transplant
> median
.40 .91 .74 1.13
TBI in conditioning regimen .41 1.11 .86 1.44
Previous autograft .74 1.08 .69 1.68
RI UCB (reference) 1.00
UD 10/10 vs. UCB .02 .57 .37 .90
UD 9/10 vs. UCB .21 .70 .39 1.23
Cytogenetics
Good (reference) 1.00
Intermediate .38 .70 .32 1.55
Poor .005 2.38 1.31 4.34
sAML .47 1.20 .74 1.94
Patient gender (female vs. male) .27 .83 .59 1.15
Age > median .80 1.04 .75 1.45
Time from diagnosis to transplant
> median
.90 1.02 .74 1.41
TBI in conditioning regimen .86 1.04 .70 1.55
Previous autograft .20 1.47 .82 2.64
NRM CB (reference) 1.00
Figure 2. OS in patients according to the 3 groups: PB HLA 10/10, PB HLA 9/10,
and UCB (CBT).
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transformed into AML at time of transplantation. The cu-
mulative incidence of relapse was similar in both groups (PB,
25%  2%; UCB, 30%  4%; P ¼ .1; Table 3). In a multivariate
analysis, risk of relapse was lower in the PB group as
compared with the UCB group (HR, 1.74; 95% CI, 1.12 to 2.70;
P ¼ .01), and a poor cytogenetic score also increased the risk
of relapse (HR, 2.39; 95% CI,1.31 to 4.35; P¼ .004) (Table 3). In
the subgroup of patients who received PB from a 9/10 mis-
matched donor, RI was 28%  5%; RI was 23%  2% in the
group of patients transplanted with 10/10 PB (10/10 versus
UCB, P ¼ .4, 9/10 versus UCB, P ¼ .32). When comparing the 3
groups, 10/10 PB, 9/10 PB, and UCB, adjusted to other cova-
riates, there was a higher risk of relapse in UCB as compared
with 10/10 PB and a similar risk of relapse between 9/10 and
UCB (10/10 versus UCB: HR, .57; 95% CI, .37 to .90; P ¼ .02; 9/
10 versus UCB: HR, .70; 95% CI, .39 to 1.23; P ¼ .21).UD 10/10 vs. UCB .003 .57 .39 .83
UD 9/10 vs. UCB .16 .71 .44 1.15
Cytogenetics
Good (reference) 1.00
Intermediate .40 1.28 .72 2.29
Poor .50 1.24 .67 2.28
sAML .23 1.29 .85 1.97
Patient gender (female vs. male) .07 .76 .57 1.02
Age > median .24 1.19 .89 1.58
Time from diagnosis to transplant
> median
.23 .84 .64 1.12
TBI in conditioning regimen .33 1.18 .85 1.65
Previous autograft .45 .77 .38 1.53
UD indicates unrelated donor; sAML, MDS transformed into AML.Survival Rates
Two-year OS and DFSwere better after PB transplantation
compared with UCB transplantation (49%  2% versus
30%  4%, P < .0001 and 44%  2% versus 28%  4%,
respectively; P < .0001). Of note, there was no statistical
difference for OS and DFS in patients who received a single
(n ¼ 49) or a double UCB transplant (n ¼ 80): OS and DFS
were 39%  7% and 24%  5% versus 35%  7% and 23%  5%,
respectively. In the multivariate analysis OS was lower after
UCB compared with PB transplantation (HR,1.72; 95% CI, 1.29
to 2.30; P ¼ .0003) along with a poor cytogenetic score (HR,
1.37; 95% CI, 1.08 to 2.59; P ¼ .02), whereas female recipients
had a better OS (HR, .77; 95% CI, .62 to 0.97; P¼ .02). DFS was
also inﬂuenced by stem cell source and was decreased with
UCB (HR, 1.70; 95% CI, 1.28 to 2.25; P ¼ .0002).
The type of conditioning regimen (comparing TBI plus
ﬂudarabine cyclophosphamide with others) had no impact
on DFS (for PB, 46% versus 42%; for CB, 25% versus 25%).
Patients who received PB from a 9/10 HLA-mismatched
donor had 2-year OS and DFS rates of 43%  5% and
36%  6%, whereas those who received PB from a 10/10 HLA-
matched donor had OS and DFS rates of 50%  3% and
45%  3% (Figure 2). Adjusted analysis within the 3 groups
showed no signiﬁcant difference between 9/10 PB transplantand UCB transplant for OS (HR, .73; 95% CI, .50 to 1.06;
P ¼ .10), whereas there was a trend to an improved adjusted
DFS for 9/10 PB compared with UCB transplants (HR, .70; 95%
CI, .49 to 1.01; P ¼ .06) (Table 4).
DISCUSSION
This study reports on outcomes in MDS patients who
received allogeneic HSCT after RIC from donors other than
HLA-matched sibling. The outcomes after unrelated PB stem
cell grafts and UCB were compared. Engraftment, OS, DFS,
and NRM were signiﬁcantly better with PB than with UCB.
M. Robin et al. / Biol Blood Marrow Transplant 21 (2015) 489e495494When the UCB group was compared with the 9/10 mis-
matched PB group, outcomes were not signiﬁcantly different
but the statistical power decreased with the 3-subset anal-
ysis (10/10, 9/10, and UCB), and results should be taken with
caution.
Outcomes after UCB has been only rarely reported in MDS
patients, whereas there are many reports on other hemato-
logical malignancies [10-12]. The largest study of MDS pa-
tients transplanted with UCB is reported by the EBMT
registry showing that OS rates can reach 46% in patients with
favorable prognostic factors [7]. In this previous study,
outcome was signiﬁcantly inﬂuenced by conditioning
regimen, with a higher NRM (>60%) after myeloablative
conditioning. In the present study and comparing with the
previous EBMT study, patients transplanted with UCB
seemed to have worse prognostic features: they were older
(57 versus 43 years) and transformation to AML was present
in more than half. Nevertheless, OS among these patients
was around 30% at 2 years, quite similar to the previous
EBMT study.
Curiously, the results were poorer than after unrelated PB
transplant in this cohort, whereas many other studies re-
ported the outcome between UCB and PB transplant to be
quite similar, particularly in acute leukemia or lymphoma
[13-16]. Brunstein et al. [13] reported the outcome of patients
with acute myeloblastic or lymphoblastic leukemia who
received a RIC, which was not signiﬁcantly different in those
receiving PB from an 8/8 or 7/8 HLA-matched donor and
those receiving UCB. A strong prognostic factor in the
Brunstein study, which we failed to ﬁnd in the present study,
was the type of conditioning regimen before UCB, with
poorer results in patients not receiving ﬂudar-
abineecyclophosphamideelow-dose TBI (TCF). Brunstein
et al. [13] reported that NRM was even lower in patients
receiving UCB after TCF than in patients receiving PB from a
7/8 HLA-mismatched donor. In addition, a collaborative
multicenter study reported similar outcomes using UCB or
PB in AML patients transplanted after RIC [14]. In this latter
study, all patients transplanted with UCB received TCF, and
all patients (n ¼ 197) were transplanted in only 3 experi-
enced centers with homogeneous comparable policy for
transplant management. In contrast, in this EBMT study,
conditioning regimen, donor choice, transplant indication,
and general management differed between 124 centers,
which can be considered aweakness but was required to lead
this study to a large number of patients. For these reasons,
conclusions should be taken with caution, even if endpoints
were adjusted for all possible confounders.
HLA matching seems to impact results in this study, and
large studies have already described an impact of HLA
mismatch, including in MDS patients [17-20]. A recent study
analyzed the outcome of MDS patients transplanted either
with a matched related donor, an 8/8 HLA-matched unre-
lated donor (n ¼ 413), or a 7/8 mismatched unrelated donor
(n¼ 112) [20]. Three-year OS rates were 45% for the 8/8 HLA-
matched unrelated donor group and 10% less for the 7/8
mismatched unrelated donor group [20], which is close to
our results showing 2-year OS rates of 50% for the 10/10
group (n ¼ 379) and 7% less for the 9/10 group (n ¼ 107). OS
after UCB transplant was also 13% less than after 9/10 PB
transplant.
The multivariate analysis for OS is not in favor of a sig-
niﬁcant advantage of 9/10 PB over the UCB transplant, but
the power of the analysis was not optimal because of the
relative low number of patients. Concerning DFS, there was atrend to poorer outcomes after use of UCB as compared with
use of 9/10 PB. In fact, HLA studies need very large cohorts to
conclude ﬁrmly on potential impact. This is why in the pre-
sent study, which was initially not designed for an HLA study,
we did not study impact of each HLA antigen on survival
rates. Larger, well-deﬁned cohorts are needed to compare
outcomes of patients receiving 9/10 unrelated donor and
UCB. However, this study reports results that seem to be
comparable.
Overall, these data suggest that in MDS patients lacking
an HLA-matched sibling, HLA-matched unrelated donor is
the best choice. When no HLA-matched donor is available,
UCB and HLA-mismatched 9/10 PB should both be consid-
ered. Given the fact that UCB is more easily available and
associated with a lower risk of chronic GVHD, this source of
stem cells appears to be a valuable option, particularly if
conducted with validated strategies that include a sufﬁcient
number of cells and a TCF conditioning regimen and when a
transplant is urgently needed.ACKNOWLEDGMENTS
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